Literature DB >> 32247874

Primary imputation methods impact efficacy results in hidradenitis suppurativa clinical trials.

John W Frew1.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32247874      PMCID： PMC7369223          DOI： 10.1016/j.jaad.2020.03.078

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  6 in total

1.  A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain.

Authors:  Alice Gottlieb; Nicola E Natsis; Francisco Kerdel; Seth Forman; Edgar Gonzalez; Gilberto Jimenez; Liliam Hernandez; Jessica Kaffenberger; Giancarlo Guido; Kathryn Lucas; Diego Montes; Michael Gold; Chad Babcock; John Simard
Journal:  J Invest Dermatol       Date:  2020-01-29       Impact factor: 8.551

2.  Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial.

Authors:  Vassiliki Tzanetakou; Theodora Kanni; Sophia Giatrakou; Alexandros Katoulis; Evangelia Papadavid; Mihai G Netea; Charles A Dinarello; Jos W M van der Meer; Dimitrios Rigopoulos; Evangelos J Giamarellos-Bourboulis
Journal:  JAMA Dermatol       Date:  2016-01       Impact factor: 10.282

3.  Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial.

Authors:  Rachel G Casseres; Lisa Prussick; Pedro Zancanaro; Brooke Rothstein; Deep Joshipura; Ami Saraiya; Yana Turkowski; Shiu Chung Au; Abdulaziz Alomran; Rana Abdat; Minawaer Abudu; Courtney Kachuk; Nicole Dumont; Alice B Gottlieb; David Rosmarin
Journal:  J Am Acad Dermatol       Date:  2020-02-07       Impact factor: 11.527

4.  Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.

Authors:  Christos C Zouboulis; Martin M Okun; Errol P Prens; Robert Gniadecki; Peter A Foley; Charles Lynde; Jamie Weisman; Yihua Gu; David A Williams; Gregor B E Jemec
Journal:  J Am Acad Dermatol       Date:  2018-06-01       Impact factor: 11.527

5.  Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.

Authors:  Alexa B Kimball; Martin M Okun; David A Williams; Alice B Gottlieb; Kim A Papp; Christos C Zouboulis; April W Armstrong; Francisco Kerdel; Michael H Gold; Seth B Forman; Neil J Korman; Evangelos J Giamarellos-Bourboulis; Jeffrey J Crowley; Charles Lynde; Ziad Reguiai; Errol-Prospero Prens; Eihab Alwawi; Nael M Mostafa; Brett Pinsky; Murali Sundaram; Yihua Gu; Dawn M Carlson; Gregor B E Jemec
Journal:  N Engl J Med       Date:  2016-08-04       Impact factor: 91.245

6.  Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab.

Authors:  E J Giamarellos-Bourboulis; M Argyropoulou; T Kanni; T Spyridopoulos; I Otto; O Zenker; R Guo; N C Riedemann
Journal:  Br J Dermatol       Date:  2020-03-04       Impact factor: 9.302
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.